Changes in plasma vascular endothelial growth factor, angiopoietins, and their receptors following surgery for breast cancer

Cancer Letters

Volumn 248, Issue 1, 2007, Pages 131-136

  Caine, Graham J ^a   Stonelake, Paul S ^b   Lip, Gregory Y H ^a   Blann, Andrew D ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

Author keywords

Angiopoietin; Breast cancer; Flt 1; Interleukin 6; Soluble P selectin; Tie 2; VEGF

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; INTERLEUKIN 6; PADGEM PROTEIN; TAMOXIFEN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE ACTIVATION; TREATMENT OUTCOME;

AGED; ANGIOPOIETINS; BREAST DISEASES; BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-6; MIDDLE AGED; RECEPTOR, TIE-2; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33847266391     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.06.011     Document Type: Article

References (34)

1. Colditz G.A. Epidemiology and prevention of breast cancer. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 768-772
2. Bray F., McCarron P., and Parkin D.M. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res. 6 (2004) 229-239
3. Folkman J. What is the evidence that tumours are angiogenesis dependent?. J. Natl. Cancer Inst. 82 (1990) 4-6
4. Feldmeden D.C., Blann A.D., and Lip G.Y.H. Angiogenesis: basic pathophysiology and implications for disease. Eur. Heart J. 24 (2003) 586-603
5. Ferrara N., and Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med. 5 (1999) 1359-1364
6. Caine G.J., Lip G.Y., and Blann A.D. Platelet-derived VEGF, Flt-1, angiopoietin-1 and P-selectin in breast and prostate cancer: further evidence for a role of platelets in tumour angiogenesis. Ann. Med. 36 (2004) 273-277
7. Nishimura R., Nagao K., Miyayama H., Matsuda M., Baba K., Yamashita H., and Fukuda M. Higher plasma vascular endothelial growth factor levels correlate with menopause, over-expression of p53, and recurrence of breast cancer. Breast Cancer 10 (2003) 120-128
8. Wu Y., Saldana L., Chillar R., and Vadgama J.V. Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment. Int. J. Oncol. 20 (2002) 509-516
9. Coskun U., Gunel N., Sancak B., Gunel U., Onuk E., Bayram O., Yilmaz E., Candan S., and Ozkan S. Significance of serum vascular endothelial growth factor, insulin-like growth factor-I levels and nitric oxide activity in breast cancer patients. Breast 12 (2003) 104-110
10. Zhao J., Yan F., Ju H., Tang J., and Qin J. Correlation between serum vascular endothelial growth factor and endostatin levels in patients with breast cancer. Cancer Lett. 204 (2004) 87-95
11. Curigliano G., Petit J.Y., Bertolini F., Colleoni M., Peruzzotti G., de Braud F., et al. Systemic effects of surgery: quantitative analysis of circulating bFGF, VEGF and TGF-beta in patients with breast cancer who underwent limited or extended surgery. Breast Cancer Res. Treat. 93 (2005) 35-40
12. Gordon M.S., and Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 69 Suppl 3 (2005) 25-33
13. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 69 Suppl 3 (2005) 11-16
14. Sfiligoi C., de Luca A., Cascone I., Sorbello V., Fuso L., Ponzone R., et al. Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Int. J. Cancer 103 (2003) 466-474
15. Currie M.J., Gunningham S.P., Han C., Scott P.A., Robinson B.A., Harris A.L., and Fox S.B. Angiopoietin-1 is inversely related to thymidine phosphorylase expression in human breast cancer, indicating a role in vascular remodeling. Clin. Cancer Res. 7 (2001) 918-927
16. Hayes A.J., Huang W.Q., Yu J., Maisonpierre P.C., Liu A., Kern F.G., Lippman M.E., McLeskey S.W., and Li L.Y. Expression and function of angiopoietin-1 in breast cancer. Br. J. Cancer 83 (2000) 1154-1160
17. Zhang G.J., and Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res. 19 (1999) 1427-1432
18. Verheul H.M., Hoekman K., Luykx-de Bakker S., Eekman C.A., Folman C.C., Broxterman H.J., and Pinedo H.M. Platelet: transporter of vascular endothelial growth factor. Clin. Cancer Res. 3 (1997) 2187-2190
19. Caine G.J., Lip G.Y.H., and Blann A.D. Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma. Thromb. Haemost. 92 (2004) 185-190
20. Blann A.D., Gurney D., Wadley M., Bareford D., Stonelake P., and Lip G.Y. Increased soluble P-selectin in patients with haematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor. Blood Coagul. Fibrinolysis 12 (2001) 43-50
21. Belgore F.M., Lip G.Y., Bareford D., Wadley M., Stonelake P., and Blann A.D. Plasma levels of vascular endothelial growth factor (VEGF) and its receptor, Flt-1, in haematological cancers: a comparison with breast cancer. Am. J. Hematol. 66 (2001) 59-61
22. Caine G.J., Blann A.D., Stonelake P.S., Ryan P., and Lip G.Y. Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1. Eur. J. Clin. Invest. 33 (2003) 883-890
23. Roselli M., Mineo T.C., Basili S., Mariotti S., Martini F., Bellotti A., et al. Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers. Thromb. Haemost. 89 (2003) 177-184
24. De Vita F., Orditura M., Lieto E., et al. Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer 100 (2004) 270-278
25. Lin S.Y., Wang Y.Y., and Sheu W.H. Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer. Clin. Endocrinol. 58 (2003) 513-518
26. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349 (2003) 427-434
27. Sancak Sancak B., Coskun U., Gunel N., Onuk E., Cihan A., Karamercan A., Yildirim Y., and Ozkan S. No association between serum levels of insulin-like growth factor-I, vascular endothelial growth factor, prolactin and clinicopathological characteristics of breast carcinoma after surgery. Int. Med. J. 34 (2004) 310-315
28. Klement G., Baruchel S., Rak J., et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105 (2000) R15-R24
29. McDowell G., Temple I., Li C., Kirwan C.C., Bundred N.J., McCollum C.N., Burton I.E., Kumar S., and Byrne G.J. Alteration in platelet function in patients with early breast cancer. Anticancer Res. 25 (2005) 3963-3966
30. Shoji M., Hancock W.W., Abe K., Micko C., Casper K.A., Baine R.M., et al. Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and VEGF in human cancer. Am. J. Pathol. 152 (1998) 399-411
31. Kuenen B.C., Levi M., Meijers J.C., Kakkar A.K., van Hinsbergh V.W., Kostense P.J., Pinedo H.M., and Hoekman K. Analysis of coagulation cascade and endothelial cell activation during inhibition of VEGF/VEGF receptor pathway in cancer patients. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 1500-1505
32. Hormbrey E., Han C., Roberts A., McGrouther D.A., and Harris A.L. The relationship of human wound vascular endothelial growth factor (VEGF) after breast cancer surgery to circulating VEGF and angiogenesis. Clin. Cancer Res. 9 (2003) 4332-4339
33. Garvin S., Nilsson U.W., and Dabrosin C. Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells. Br. J. Cancer 93 (2005) 1005-1010
34. Meunier-Carpentier S., Dales J.P., Djemli A., Garcia S., Bonnier P., Andrac-Meyer L., Lavaut M.N., Allasia C., and Charpin C. Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma. Int. J. Oncol. 26 (2005) 977-984